Yan B, Zhang B, Chu T, Zhang W, et al. Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study. Lung Cancer 2025;205:108627.
PMID: 40555061